The Care Ledger

The market Biotech groups file the second lawsuit against Medicare's international drug price pilot

Search
Tuesday, November 17, 2026Today's Paper From the publisher Free hospital price search Published bysoro
The Care Ledger

The market

Biotech groups file the second lawsuit against Medicare's international drug price pilot

BIO and two California trade groups asked a federal court on Friday to throw out the GLOBE model, which from January ties Medicare Part B rebates on certain drugs to prices in 19 other countries.

Four small glass vials of liquid medicine in an open white carton
Glass drug vials in a carton. Photo: Lee Haywood from Wollaton, Nottingham, England, via Wikimedia Commons (CC BY-SA 2.0)

The Biotechnology Innovation Organization (BIO), California Life Sciences and Biocom California filed suit on Friday in the US District Court for the Northern District of California to block the Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory Medicare payment test that starts January 1, 2027. The complaint1 asks the court to declare the model unlawful, vacate it and stay its effective date. It is the second industry suit against the model, after the Pharmaceutical Research and Manufacturers of America (PhRMA) sued in Washington on October 7.

GLOBE is the Trump administration's attempt to bring foreign drug prices into Medicare's payment for infused and injected drugs. Under the final rule4, published October 2, manufacturers of covered drugs owe Medicare a rebate when the drug's US price exceeds a benchmark built from the lowest price in 19 reference countries, including Canada, Germany, Japan and the United Kingdom. Beneficiary coinsurance on those drugs is tied to the benchmark as well. The model applies in geographic areas chosen to cover about 25% of Original Medicare Part B enrollees and covers single-source drugs and sole-source biologics with more than $100 million a year in Original Medicare Part B spending.

What is at stake for what people pay

For people on Original Medicare, the stakes are specific but, by CMS's own count, small. The final rule estimates the model will save $440 million in Medicare Part B net spending over its seven-year payment period, against total Original Medicare Part B drug spending of $81.90 billion in 2025. Beneficiaries would save an estimated $111 million in all: $50 million in coinsurance and $61 million in Part B premiums, according to the rule's impact analysis.

Those figures are far below what CMS projected a year ago. The proposed rule estimated $8.4 billion in Original Medicare Part B savings over the payment period and $1.4 billion in beneficiary premium savings. The comparable figures in the final rule are $298 million and $111 million. CMS attributes much of the drop to its assumption that manufacturers that signed agreements under its voluntary GENEROUS model by August 17, 2026 will be waived out of GLOBE, and to drugs it removed from the model after public comments.

The trade groups seize on that math. Their complaint says CMS did not dispute commenters' estimate that only about 0.3% of beneficiaries would see any change in what they pay. BIO's press release2 says the three groups represent more than one-third of US biotech companies.

The legal claims

The complaint raises three counts. The first says the rule exceeds the authority Congress gave CMS's Innovation Center under section 1115A of the Social Security Act to test payment models, and instead rewrites the Part B inflation rebate statute. The second says it violates the Appropriations Clause and related statutes. The third says it violates separation of powers and nondelegation principles. Joe Franklin, BIO's chief legal and policy officer, said in the release that CMS "crossed the limits Congress placed on its authority."

PhRMA's complaint6, filed in the US District Court for the District of Columbia, makes two claims, that GLOBE is contrary to law and that it violates the Constitution, and also asks the court to vacate the rule. CMS did not immediately respond to a request for comment from STAT3, which first reported the BIO filing on Saturday.

How the model got here

The final rule takes effect November 30, 2026. It describes GLOBE as a test of an alternative way to calculate the Part B drug inflation rebate, run through the Innovation Center, whose model-testing authority is the legal footing both lawsuits attack. Covered drugs come from oncology, rheumatology, immunology, ophthalmology and endocrinology, with exceptions, according to the CMS model page5.

What comes next

Data collection under GLOBE starts January 1, 2027. The five performance years run from April 1, 2027 to March 31, 2032, and that April date is when beneficiaries in the selected areas would first see lower coinsurance. Rebate invoicing and reconciliation run through March 31, 2034. Neither court has set a hearing date in the pages reviewed for this article. The question for the next eight weeks is whether either court stays the rule before the January start, which would leave Part B payment and the 20% coinsurance on these drugs tied to US prices for now.

  • 01

    New Mexico weighs a $2 million medical debt buyback

    House Democrats propose spending $2 million over three years with the nonprofit Undue Medical Debt to cancel more than $200 million owed by an estimated 100,000 to 160,000 residents, with no application required. Undue describes the $200 million as an upper bound, and the plan needs both chambers and Governor-elect Deb Haaland, the Albuquerque Journal reported on Sunday.

    Albuquerque Journal, NM House Democrats

  • 02

    Three Medicare final rules publish Monday

    The 2027 physician fee schedule, the 2027 home health payment rule and the Medicare drug price negotiation final rule are on public inspection for the November 9 Federal Register, with the CARE deregulatory proposed rule following on November 10. The negotiation rule has CMS selecting up to 20 more drugs by February 1, 2027 for prices effective in 2029.

    Federal Register public inspection, CMS

  • 03

    Comments open on standardizing hospital price files

    The 2027 hospital outpatient payment final rule published in Friday's Federal Register carries a request for information on making hospital price transparency data more standardized and comparable. Comments are due January 4, 2027.

    Federal Register

  • 04

    A hockey team's foundation retires $1 million in veterans' medical debt

    The Pittsburgh Penguins Foundation and ForgiveCo say they eliminated $1 million in medical debt for about 400 randomly selected local veterans, who are notified by email, text and letter rather than applying.

    Pittsburgh Penguins, CBS Pittsburgh

Every figure in this story was checked against these sources on Sunday, November 8, 2026.

  1. 01Biotechnology Innovation Organization, California Life Sciences Association and Biocom California v. Kennedy et al., Complaint for Declaratory and Injunctive Relief, Case No. 3:26-cv-13372 (N.D. Cal.), filed November 6, 2026bio.org
  2. 02Biotechnology Innovation Organization, "BIO, Biocom, and California Life Sciences Sue to Block CMS GLOBE Rule", November 6, 2026bio.org
  3. 03STAT, "BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries", November 7, 2026statnews.com
  4. 04Centers for Medicare & Medicaid Services, "Global Benchmark for Efficient Drug Pricing (GLOBE) Model" (final rule, CMS-5545-F), Federal Register 91 FR 62936, October 2, 2026federalregister.gov
  5. 05Centers for Medicare & Medicaid Services, "Global Benchmark for Efficient Drug Pricing (GLOBE) Model" (model page), updated October 2, 2026cms.gov
  6. 06Pharmaceutical Research and Manufacturers of America v. Kennedy et al., Complaint for Declaratory and Injunctive Relief, Case No. 1:26-cv-03498 (D.D.C.), filed October 7, 2026 (copy hosted by STAT)statnews.com
  7. 07Albuquerque Journal, "New Mexico House Democrats propose buying back $200 million in medical debt", November 8, 2026abqjournal.com
  8. 08New Mexico House Democrats, "House Democrats Propose Statewide Medical Debt Relief Plan", October 30, 2026nmhousedemocrats.com
  9. 09Federal Register, public inspection documents for November 9 and 10, 2026 (documents 2026-22743, 2026-22750, 2026-22792, 2026-22812), accessed November 8, 2026federalregister.gov
  10. 10Centers for Medicare & Medicaid Services, "CMS Final Rule Strengthens, Supports Lasting Drug Savings", November 5, 2026cms.gov
  11. 11Centers for Medicare & Medicaid Services, "Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems ... Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data" (final rule), Federal Register 91 FR 70284, November 6, 2026federalregister.gov
  12. 12Pittsburgh Penguins, "Pittsburgh Penguins Foundation and ForgiveCo eliminate $1 million in medical debt for local veterans", November 6, 2026nhl.com
  13. 13CBS Pittsburgh, "Pittsburgh Penguins Foundation erases medical debt for veterans", November 7, 2026cbsnews.com
  14. PhotoGlass drug vials in a carton. Photo: Lee Haywood from Wollaton, Nottingham, England, via Wikimedia Commons (CC BY-SA 2.0).commons.wikimedia.org
  1. The market

    Maryland finalizes the first state payment limits on a drug, for Ozempic and Jardiance

    Starting in January, state and local government health plans in Maryland can cap what they pay for the two drugs, and a 2025 law lets the board extend the limits to private insurance from 2028.

    3 min read

  2. The market

    Jefferson Health loses $81 million in a quarter as it presses insurers for higher rates

    Philadelphia's largest health system is using weak results to argue for higher commercial rates, six weeks before its contracts with three Blue Cross insurers expire.

    2 min read

  3. The market

    CVS says GLP-1 drugs would pay for themselves at about $350 a month

    CVS Health's own claims study finds that weight-loss and diabetes drugs cut hospital use but still raise what employers and plans spend per member, and it names the net price at which that would stop.

    3 min read

  4. The market

    Surgery Partners rejects a $28 bid, takes $25 a share from Bon Secours Mercy's HealthSpan

    The surgery center chain chose a hospital system's raised offer over a higher cash bid, reported to be UnitedHealth's, because the board judged the bigger number less likely to close.

    3 min read